Clinical trial NCT01621581 - References

Parkinson's Disease — AAV2-GDNF for Advanced Parkinson s Disease

Citation(s)

•   Airaksinen MS, Saarma M
  The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002 May;3(5):383-94. doi: 10.1038/nrn812.
•   Backman CM, Shan L, Zhang YJ, Hoffer BJ, Leonard S, Troncoso JC, Vonsatel P, Tomac AC
  Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol Cell Endocrinol. 2006 Jun 27;252(1-2):160-6. doi: 10.1016/j.mce.2006.03.013. Epub 2006 Apr 27.
•   Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ
  Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 2000 Dec 15;886(1-2):82-98. doi: 10.1016/s0006-8993(00)02915-2.

A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease

Details for clinical trial NCT01621581